Esperion Therapeutics | ESPR - Cost Of Sales

Stock Price
3.49
Daily Change
0.10 2.80%
Monthly
-1.83%
Yearly
85.37%
Q1 Forecast
2.70

Esperion Therapeutics reported $51.63M in Cost of Sales for its fiscal quarter ending in September of 2024.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Alnylam Pharmaceuticals USD 200.15M 57.2M Sep/2025
Amarin USD 16.89M 18.51M Mar/2025
Amgen USD 1.79B 128M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 144.93M 10M Sep/2025
Cipla INR 29.1B 1.16B Dec/2025
CSL USD 1.79B 2.15B Jun/2025
Cytokinetics USD 112.55M 12.71M Jun/2025
Daiichi Sankyo JPY 118.28B 37.7B Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Esperion Therapeutics USD 51.63M 22.2M Sep/2024
Geron USD 1.04M 147K Sep/2025
Grifols EUR 1.32B 22.75M Sep/2025
Halozyme Therapeutics USD 73M 8.88M Sep/2025
Heron Therapeutics USD 9.46M 1.61M Sep/2024
Ionis Pharmaceuticals USD 2.34M 1.81M Sep/2025
Merck USD 3.32B 531M Dec/2025
Minerva Neurosciences 386K 31K Jun/2024
Moderna USD 207M 88M Sep/2025
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Pfizer USD 6.29B 2.12B Dec/2025
PTC Therapeutics USD 23.32M 7.83M Sep/2025
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Sanofi EUR 4.29B 421M Dec/2025
Sarepta Therapeutics USD 151.45M 1.77M Sep/2025
United Therapeutics USD 100.9M 74.3M Sep/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024